Amgen today announced that new data from its expanding inflammation pipeline and marketed portfolio will be presented at the European Academy of Dermatology and Venereology 30 th Congress, which will take place virtually Sept. 29 Oct. 2 . In a late-breaking data presentation, detailed results from a Phase 2 moderate-to-severe atopic dermatitis study of AMG 451KHK4083, a potential first-in-class anti-OX40 monoclonal …
– Amgen (NASDAQ: AMGN) today announced that new data from its expanding inflammation pipeline and marketed portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 30 th Congress, which will take place virtually Sept. 29 Oct. 2 .
In a late-breaking data presentation, detailed results from a Phase 2 moderate-to-severe atopic dermatitis study of AMG 451/KHK4083, a potential first-in-class anti-OX40 monoclonal antibody jointly under development by Amgen and Kyowa Kirin Co., Ltd. (TSE: 4151) for the treatment of moderate-to-severe atopic dermatitis, will be presented. Additionally, new 32-week outcomes data from the Phase 3 ADVANCE trial investigating the efficacy and safety of Otezla (apremilast) to improve psoriasis symptoms and involvement in special areas (scalp or nails) in adults with mild-to-moderate plaque psoriasis will also be presented.
“Amgen looks forward to sharing new late-breaking research at EADV alongside our partners at Kyowa Kirin, highlighting a potential new treatment option for the millions of people...
Read Full Story: https://investingnews.com/news/biotech-investing/amgen-to-showcase-new-data-from-inflammation-portfolio-at-eadv-virtual-congress-2021/
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.